Form 4: SAB Biotherapeutics Director, Jeffrey G. Spragens, Receives Stock Option Grant

Director Jeffrey G. Spragens receives a stock option grant for 20,000 shares of SAB Biotherapeutics, Inc.

Summary

• Jeffrey G. Spragens, a director of SAB Biotherapeutics, Inc. (SABS), was granted a stock option to purchase 20,000 shares of common stock on July 15, 2024.
• The exercise price of the stock option is $2.9.
• The options vest in two equal annual installments starting on July 15, 2025, and July 15, 2026.
• The stock option expires on July 15, 2034.
• The grant was made under the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a standard stock option grant. It's a routine event, neither particularly positive nor negative on its own.

Positives

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the equity grant suggests an expectation of continued service and contribution from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants to board members are a standard practice across the biotechnology industry.
• The size of the grant and vesting schedule are typical for companies of SAB Biotherapeutics' size and stage of development.
• Comparable companies such as Vir Biotechnology or Regeneron Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the director's efforts lead to an increase in the company's stock price.
• The grant incentivizes the director to contribute to the company's success, which could indirectly benefit employees and other stakeholders.

Key Dates